How to cite item

Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma

   
@article{CCO25592,
	author = {Veronica Mollica and Vincenzo Di Nunno and Francesco Massari},
	title = {Pembrolizumab plus axitinib: a new treatment option for patients  with metastatic renal cell carcinoma},
	journal = {Chinese Clinical Oncology},
	volume = {8},
	number = {Suppl 1},
	year = {2019},
	keywords = {},
	abstract = {The treatment scenario for patients with metastatic renal cell carcinoma (mRCC) is witnessing its third revolution: the first was the advent of anti-angiogenic targeted therapies, consisting in tyrosine-kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF); the second was the introduction of immunotherapy, consisting in immune checkpoint inhibitors (ICI), like anti-programmed death 1 (PD-1) receptor or anti-programmed death ligand 1 (PD-L1); the third and current revolution is the advent of ICI and TKIs combination.},
	issn = {2304-3873},	url = {https://cco.amegroups.org/article/view/25592}
}